Literature DB >> 15622611

Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397).

W Philip M Mayles1, A Rollo Moore, Edwin G A Aird, A Margaret Bidmead, David P Dearnaley, Sue E Griffiths, A P Jim Warrington.   

Abstract

BACKGROUND AND
PURPOSE: In order to ensure the validity of the outcome of the Medical Research Council's 'RTO1 trial' of dose escalation in conformal radiotherapy for prostate cancer it was considered important that the quality of treatment delivery should meet an adequate standard across all contributing centres. A questionnaire was therefore devised to ensure that all aspects of the planning and delivery process were adequately covered. PATIENTS AND METHODS: The questionnaire considered each step in the planning and delivery process and drew the attention of the participants to the specific requirements of the trial. Before entering patients into the trial each participating centre had to complete the questionnaire and an outlining exercise (reported elsewhere).
RESULTS: It was not practicable to define a detailed universally acceptable protocol for the whole process of delivery of conformal radiotherapy, not least because of the different equipment available for planning and treatment in different centres. The questionnaire identified some areas of difference in practice between centres where there may be a need for the development of a consensus as to best practice, particularly in the area of patient set-up. Occasionally it was necessary to follow up responses to questions that had been misunderstood or inadequately answered, but in most cases these issues proved to be easily resolved.
CONCLUSIONS: The questionnaire proved to be a useful self-assessment tool as well as enabling the quality assurance group to ensure that the standards of the trial were being met. Subsequent follow-up visits confirmed the usefulness and validity of this self assessment process.

Entities:  

Mesh:

Year:  2004        PMID: 15622611     DOI: 10.1016/j.radonc.2004.08.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Radiotherapy dosimetry audit: three decades of improving standards and accuracy in UK clinical practice and trials.

Authors:  Catharine H Clark; Edwin G A Aird; Steve Bolton; Elizabeth A Miles; Andrew Nisbet; Julia A D Snaith; Russell A S Thomas; Karen Venables; David I Thwaites
Journal:  Br J Radiol       Date:  2015-09-02       Impact factor: 3.039

2.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

Review 3.  Quality assurance for clinical trials.

Authors:  Geoffrey S Ibbott; Annette Haworth; David S Followill
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

4.  Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397).

Authors:  Agnieszka Lemanska; Tao Chen; David P Dearnaley; Rajesh Jena; Matthew R Sydes; Sara Faithfull
Journal:  Qual Life Res       Date:  2017-03-28       Impact factor: 4.147

5.  Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).

Authors:  S Stanley; S Griffiths; M R Sydes; A R Moore; I Syndikus; D P Dearnaley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-06-18       Impact factor: 4.126

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.